Evidence map›Paper›PMID 26729432›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy.

Isabel J Boero, Anthony J Paravati, Beibei Xu, Ezra E W Cohen, Loren K Mell, Quynh-Thu Le, James D Murphy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Trial
  3. Trial
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. A GORTEC survey on low-risk CTV-P2 delineation in head and neck cancers.Clinical and translational radiation oncology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Isabel J BoeroIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China.
Anthony J ParavatiIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China.
Beibei XuIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China.
Ezra E W CohenIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China.
Loren K MellIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China.
Quynh-Thu LeIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China.
James D MurphyIsabel J. Boero, Anthony J. Paravati, Ezra E.W. Cohen, Loren K. Mell, and James D. Murphy, University of California San Diego, La Jolla; Quynh-Thu Le, Stanford University, Stanford, CA; and Beibei Xu, Peking University, Beijing, People's Republic of China. j2murphy@ucsd.edu.
University of California, San Diego · USStanford University · US

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
NCATS NIH HHS KL2 TR001444NCATS NIH HHS TL1 TR001443
6 · The paper itself

Abstract

purposeOver the past decade, intensity-modulated radiation therapy (IMRT) has replaced conventional radiation techniques in the management of head-and-neck cancers (HNCs). We conducted this population-based study to evaluate the influence of radiation oncologist experience on outcomes in patients with HNC treated with IMRT compared with patients with HNC treated with conventional radiation therapy.

methodsWe identified radiation providers from Medicare claims of 6,212 Medicare beneficiaries with HNC treated between 2000 and 2009. We analyzed the impact of provider volume on all-cause mortality, HNC mortality, and toxicity end points after treatment with either conventional radiation therapy or IMRT. All analyses were performed by using either multivariable Cox proportional hazards or Fine-Gray regression models controlling for potential confounding variables.

resultsAmong patients treated with conventional radiation, we found no significant relationship between provider volume and patient survival or any toxicity end point. Among patients receiving IMRT, those treated by higher-volume radiation oncologists had improved survival compared with those treated by low-volume providers. The risk of all-cause mortality decreased by 21% for every additional five patients treated per provider per year (hazard ratio [HR], 0.79; 95% CI, 0.67 to 0.94). Patients treated with IMRT by higher-volume providers had decreased HNC-specific mortality (subdistribution HR, 0.68; 95% CI, 0.50 to 0.91) and decreased risk of aspiration pneumonia (subdistribution HR, 0.72; 95% CI, 0.52 to 0.99).

conclusionPatients receiving IMRT for HNC had improved outcomes when treated by higher-volume providers. These findings will better inform patients and providers when making decisions about treatment, and emphasize the critical importance of high-quality radiation therapy for optimal treatment of HNC.

Indexed as

Clinical CompetenceCause of DeathFemaleHead and Neck NeoplasmsHumansMaleMedicareOutcome and Process Assessment, Health CareRadiotherapy, Intensity-ModulatedRetrospective StudiesSEER ProgramSurvival RateUnited States

Identifiers

PMID26729432
PMCPMC4872027
OpenAlexW2226272315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.